1. Current and novel therapeutic opportunities for systemic therapy in biliary cancer
- Author
-
Giovanni Brandi, Giulia Mentrasti, Vincenzo Cardinale, Jose J.G. Marin, Maite G. Fernandez-Barrena, John Bridgewater, Oreste Segatto, Angela Lamarca, Rocio I.R. Macias, Arndt Vogel, Jesus M. Banales, Patricia Munoz-Garrido, Pilar Acedo, Ana Landa-Magdalena, Cecília M. P. Rodrigues, Juan W. Valle, Marco Marzioni, Chiara Braconi, Adelaida La Casta, Pedro M. Rodrigues, Simona Tavolari, Joachim C. Mertens, Ana Da Silva Ruivo, Maria Giuseppina Prete, Marin J.J.G., Prete M.G., Lamarca A., Tavolari S., Landa-Magdalena A., Brandi G., Segatto O., Vogel A., Macias R.I.R., Rodrigues P.M., Casta A.L., Mertens J., Rodrigues C.M.P., Fernandez-Barrena M.G., Da Silva Ruivo A., Marzioni M., Mentrasti G., Acedo P., Munoz-Garrido P., Cardinale V., Banales J.M., Valle J.W., Bridgewater J., and Braconi C.
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,medicine.medical_treatment ,Review Article ,biliary tract cancer, chemotherapy ,Systemic therapy ,Cholangiocarcinoma ,03 medical and health sciences ,0302 clinical medicine ,Stroma ,Internal medicine ,Tumor Microenvironment ,Medicine ,Humans ,Molecular Targeted Therapy ,Precision Medicine ,Chemotherapy ,Clinical Trials as Topic ,Molecular medicine ,business.industry ,Liquid Biopsy ,Correction ,Biliary cancer ,Phenotype ,3. Good health ,Strategies for treating patients ,Biliary Tract Neoplasms ,Liver ,Biliary tract ,Drug Resistance, Neoplasm ,030220 oncology & carcinogenesis ,Molecular targets ,Biliary tract cancer ,Immunotherapy ,business ,Biliary tract cancers (BTCs) ,Adjuvant ,Aggressive malignancies - Abstract
Biliary tract cancers (BTCs) are a group of rare and aggressive malignancies that arise in the biliary tree within and outside the liver. Beyond surgical resection, which is beneficial for only a small proportion of patients, current strategies for treating patients with BTCs include chemotherapy, as a single agent or combination regimens, in the adjuvant and palliative setting. Increased characterisation of the molecular landscape of these tumours has facilitated the identification of molecular vulnerabilities, such as IDH mutations and FGFR fusions, that can be exploited for the treatment of BTC patients. Beyond targeted therapies, active research avenues explore the development of novel therapeutics that target the crosstalk between cancer and stroma, the cellular pathways involved in the regulation of cell death, the chemoresistance phenotype and the dysregulation of RNA. In this review, we discuss the therapeutic opportunities currently available in the management of BTC patients, and explore the strategies that can support the implementation of precision oncology in BTCs, including novel molecular targets, liquid biopsies and patient-derived predictive tools.
- Published
- 2020
- Full Text
- View/download PDF